Suppliers and packagers for BYETTA

BYETTA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca Ab	BYETTA	exenatide synthetic	INJECTABLE;SUBCUTANEOUS	021773	NDA	AstraZeneca Pharmaceuticals LP	0310-6512-01	1 CARTRIDGE in 1 CARTON (0310-6512-01) / 1.2 mL in 1 CARTRIDGE	2014-12-10
Astrazeneca Ab	BYETTA	exenatide synthetic	INJECTABLE;SUBCUTANEOUS	021773	NDA	AstraZeneca Pharmaceuticals LP	0310-6524-01	1 CARTRIDGE in 1 CARTON (0310-6524-01) / 2.4 mL in 1 CARTRIDGE	2014-12-12

Byetta Drug Supply Chain Analysis

Last updated: February 19, 2026

What are the primary components of Byetta's supply chain?

Byetta (exenatide) is a glucagon-like peptide-1 (GLP-1) receptor agonist used to manage type 2 diabetes. Its supply chain involves the sourcing of active pharmaceutical ingredient (API), formulation and manufacturing of the final drug product, packaging, and distribution. Key suppliers are concentrated in API manufacturing, contract manufacturing organizations (CMOs) for drug product formulation, and specialized packaging providers. Intellectual property surrounding Byetta's formulation and manufacturing processes influences supplier selection and market dynamics.

Who are the key suppliers for Byetta's Active Pharmaceutical Ingredient (API)?

The primary API for Byetta is exenatide. Exenatide is a synthetic peptide, and its manufacturing is complex, requiring specialized biotechnology capabilities. Historically, Novo Nordisk has been a significant player in the peptide manufacturing space, and while specific current API suppliers are not publicly disclosed by Eli Lilly and Company (the marketer of Byetta), it is reasonable to infer that peptide synthesis specialists are involved. Companies with expertise in recombinant DNA technology and solid-phase peptide synthesis are essential for producing exenatide.

• Peptide Synthesis Specialists: Companies capable of large-scale, high-purity peptide manufacturing are critical. This includes facilities equipped for fermentation, purification, and quality control of peptide-based APIs.
• Contract Manufacturing Organizations (CMOs) with Biologics Expertise: CMOs that specialize in producing complex biologics, including peptides, would be potential suppliers. These organizations often have dedicated facilities and regulatory compliance for API production.

While specific contractual relationships are proprietary, the general landscape of API sourcing for complex biologics points to a limited number of highly specialized providers globally. Fluctuations in demand, regulatory changes, and patent expiry can impact the availability and pricing of exenatide API.

Which Contract Manufacturing Organizations (CMOs) are involved in Byetta's drug product formulation and fill-finish?

The formulation of Byetta involves converting the exenatide API into a stable, injectable solution. This requires sterile manufacturing environments and specialized fill-finish capabilities. Eli Lilly and Company, as the drug's marketer, likely manages its formulation and manufacturing through a combination of in-house facilities and contracted CMOs.

CMOs specializing in sterile injectable drug products are integral to the Byetta supply chain. These organizations possess the infrastructure and regulatory approvals to handle the aseptic filling of vials or pre-filled pens. Their services typically include:

• Formulation Development and Optimization: Ensuring the stability and efficacy of the exenatide solution.
• Aseptic Filling: High-speed, sterile filling of the drug product into its final container.
• Lyophilization (if applicable): For certain formulations, freeze-drying might be employed to enhance shelf-life, though Byetta is typically a liquid formulation.
• Quality Control and Assurance: Rigorous testing throughout the manufacturing process.

While specific CMO partners for Byetta are not publicly detailed by Eli Lilly, common players in the sterile injectable CMO market include:

• Catalent Pharma Solutions: A major provider of drug formulation, development, and manufacturing services, including sterile injectables.
• Lonza Group: A global supplier to the pharmaceutical, biotech, and nutrition markets, with extensive capabilities in biopharmaceutical manufacturing.
• Thermo Fisher Scientific (Patheon Brand): Offers a broad range of pharmaceutical development and manufacturing services, including sterile fill-finish.

The selection of CMOs is based on capacity, technological capabilities, regulatory compliance history, and cost. Eli Lilly's internal manufacturing capacity also plays a significant role in determining the extent of CMO reliance.

What packaging and delivery device suppliers are critical for Byetta?

Byetta is administered via subcutaneous injection. The delivery device, often a pre-filled pen or a vial with accompanying syringes, is a crucial component of the product's usability and market success. Suppliers of these specialized devices and packaging materials are vital.

• Pen Device Manufacturers: Companies specializing in the design and manufacturing of auto-injector pens are critical. These devices integrate sophisticated engineering for dose accuracy and user convenience. Key players in this sector include:

  • Ypsomed: A Swiss company that develops and manufactures injection and infusion systems for self-medication, including pen injectors.
  • Phillips-Medisize (now part of Molex): Designs and manufactures drug delivery devices, including auto-injectors and pen systems.
  • Gerresheimer: A manufacturer of pharmaceutical packaging and drug delivery devices, including medical plastics and pen components.

• Primary Packaging Suppliers: Suppliers of vials, stoppers, seals, and syringes are also essential. These materials must meet stringent pharmaceutical standards for inertness and sterility.

  • Schott AG: A global leader in pharmaceutical glass, including vials and syringes.
  • West Pharmaceutical Services: A leading manufacturer of packaging components and delivery systems for injectable drugs, including stoppers and seals.

• Secondary Packaging Providers: Suppliers of cartons, labels, and leaflets are responsible for the product's external packaging, ensuring compliance with regulatory labeling requirements.

The integration of these components requires close collaboration between the pharmaceutical company and its diverse supplier base. Innovation in delivery devices can significantly impact patient adherence and market differentiation for products like Byetta.

What is the patent landscape surrounding Byetta and its implications for suppliers?

The patent landscape for Byetta has evolved since its initial launch. Original patents covered the exenatide molecule itself, as well as its therapeutic uses and specific formulations. As these foundational patents expire, the market opens to generic competition, which can significantly alter the supplier dynamics.

• Compound Patents: The primary patents covering the exenatide molecule have largely expired in major markets. This allows for the development and potential approval of generic versions of exenatide.
• Formulation and Method of Use Patents: Eli Lilly holds and has held patents related to specific formulations of Byetta (e.g., extended-release versions, specific excipients used) and methods of administering the drug. The expiry or successful challenge of these patents can also influence market entry for competitors.
• Delivery Device Patents: Patents covering the specific design of the pre-filled pen delivery system can provide extended market exclusivity. The strength and duration of these device patents are critical for protecting market share.

Implications for Suppliers:

• Increased Competition for Generic API: As patents expire, there is increased demand for exenatide API from generic drug manufacturers. This can lead to greater competition among API suppliers and potentially lower API prices, but also requires suppliers to meet stringent quality and regulatory standards for multiple clients.
• CMO Opportunities: Generic manufacturers will also require CMOs for formulation and fill-finish. This expands opportunities for CMOs that can handle bio-similar or generic peptide production.
• Focus on Innovation in Delivery Devices: For branded products, continued patent protection on novel delivery devices can deter generic entry. Suppliers of innovative drug delivery systems remain valuable partners for originator companies.
• Supply Chain Security: With the potential for increased generic activity, ensuring a robust and secure supply chain for both branded and generic versions becomes paramount. This involves qualifying multiple suppliers and managing geopolitical risks.

The ongoing patent litigation and the lifecycle management strategies of Eli Lilly and potential generic competitors directly shape the demand for services and products from API manufacturers, CMOs, and device suppliers.

Key Takeaways

• Byetta's supply chain relies on specialized manufacturers for its synthetic peptide API, exenatide.
• Contract Manufacturing Organizations (CMOs) with expertise in sterile injectable formulation and fill-finish are critical for producing the final drug product.
• Suppliers of advanced drug delivery devices, such as pre-filled pens, are integral to Byetta's market offering.
• The patent expiration of the exenatide molecule has opened the door for generic competition, impacting demand and competition among API and CMO suppliers.
• Patents on specific formulations and delivery devices continue to play a role in market exclusivity for the branded product.

FAQs

What is the difference between exenatide and Byetta?

Exenatide is the active pharmaceutical ingredient (API) in the brand-name drug Byetta. Byetta is the finished drug product that contains exenatide and other inactive ingredients, formulated for administration to patients.

How is exenatide API manufactured?

Exenatide is a synthetic peptide. Its manufacturing typically involves complex chemical synthesis processes, such as solid-phase peptide synthesis, or biotechnological methods like recombinant DNA technology followed by purification.

What are the main challenges in manufacturing peptide-based drugs like exenatide?

Manufacturing peptide-based drugs presents challenges including achieving high purity and yield, ensuring stability of the peptide molecule, controlling complex synthesis reactions, and meeting stringent regulatory requirements for biologics.

Can Byetta be manufactured by any pharmaceutical company once its patents expire?

Once the primary compound patents for exenatide expire, other companies can seek approval to market generic versions of exenatide. However, they must still demonstrate bioequivalence to Byetta and meet all regulatory requirements for manufacturing and quality. Patents on specific formulations or delivery devices may still offer market exclusivity for certain versions of the drug.

What is the role of a CMO in the Byetta supply chain?

A Contract Manufacturing Organization (CMO) can be responsible for various stages of Byetta's production, including formulating the exenatide API into the final injectable solution and performing the sterile fill-finish operations into vials or pens.

Citations

[1] Eli Lilly and Company. (n.d.). Byetta (exenatide) Prescribing Information. U.S. Food and Drug Administration. Retrieved from [FDA Website - specific prescribing information link would be provided if publicly accessible]

[2] Ypsomed. (n.d.). Pen Injectors. Retrieved from [Ypsomed Official Website]

[3] Phillips-Medisize. (n.d.). Drug Delivery Devices. Retrieved from [Phillips-Medisize Official Website]

[4] Gerresheimer. (n.d.). Drug Delivery Solutions. Retrieved from [Gerresheimer Official Website]

[5] Schott AG. (n.d.). Pharmaceutical Packaging. Retrieved from [Schott AG Official Website]

[6] West Pharmaceutical Services. (n.d.). Drug Containment & Delivery. Retrieved from [West Pharmaceutical Services Official Website]

[7] Catalent Pharma Solutions. (n.d.). Sterile Manufacturing. Retrieved from [Catalent Pharma Solutions Official Website]

[8] Lonza Group. (n.d.). Biologics Manufacturing. Retrieved from [Lonza Group Official Website]

[9] Thermo Fisher Scientific. (n.d.). Patheon Pharmaceutical Services. Retrieved from [Thermo Fisher Scientific Official Website]